BioSpace1d
Dyne’s Duchenne Exon Skipping Oligomer Shows ‘Differentiated’ Clinical Effect
Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys ...
GlobalData on MSN21d
FDA removes clinical hold on Entrada’s Duchenne therapy
Entrada Therapeutics can plough on with the development of its Duchenne muscular dystrophy (DMD) therapy, ENTR-601-44, now that the US Food and Drug Administration (FDA) has lifted a two-year clinical ...
Endpoints News2d
Avid­i­ty seeks to 'set the stan­dard' as it heads to FDA with Duchenne drug
Avidity Biosciences shared Monday that its RNA drug for people with certain mutations of Duchenne muscular dystrophy ...
Avidity Biosciences announces del-zota topline data from EXPLORE44 trial
Avidity Biosciences (RNA) announced del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular dystrophy ...
Clinical Trials Arena on MSN1d
Dyne’s DMD trial advances patient mobility and dystrophin expression
The Phase I/II Deliver trial sought to establish the impact of DYNE-251 on several mobility-related endpoints, seeing an ...
Avidity Biosciences announces ‘positive’ data from Phase 1/2 EXPLORE44 trial
Avidity Biosciences (RNA) announced positive del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular ...
Yahoo Finance23d
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
Nearly half of those living with Duchenne who are amenable to exon 44 skipping are adults. ELEVATE-44-102 will provide clinical experience from this important population for our growing data package ...
PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...